Detection of mycolactone A/B in Mycobacterium ulcerans - Infected human tissue

PLoS Neglected Tropical Diseases

Volumn 4, Issue 1, 2010, Pages

  Sarfo, Fred Stephen ^a   Phillips, Richard O ^a,b   Rangers, Brian ^c   Mahrous, Engy A ^c   Lee, Richard E ^c   Tarelli, Edward ^d   Asiedu, Kingsley B ^e   Small, Pamela L ^c   Wansbrough Jones, Mark H ^d  

^a KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; ANTIBIOTIC AGENT; BACTERIAL TOXIN; LACTONE; LIPID; MYCOLACTONE A; MYCOLACTONE B; POLYKETIDE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; MYCOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BACTERIUM DETECTION; BURULI ULCER; CELL CULTURE; CELL LINE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ELECTROSPRAY MASS SPECTROMETRY; FIBROBLAST; FRAGMENTATION REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; MASS SPECTROMETRY; MOLECULE; MYCOBACTERIUM ULCERANS; SCHOOL CHILD; THIN LAYER CHROMATOGRAPHY; ANIMAL; CHEMISTRY; DRUG EFFECT; FEMALE; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; MOUSE; PATHOLOGY; PHYSIOLOGY; SKIN;

ADOLESCENT; ADULT; ANIMALS; BACTERIAL TOXINS; BURULI ULCER; CELL LINE; CHILD; CHROMATOGRAPHY, THIN LAYER; FEMALE; HUMANS; MACROPHAGES; MALE; MICE; MYCOBACTERIUM ULCERANS; SKIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 76249128452     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000577     Document Type: Article

References (23)

1. Wansbrough-Jones M, Phillips R (2006) Buruli ulcer: emerging from obscurity. Lancet 367: 1849-1858.
2. Evans MR, Phillips R, Etuaful SN, Amofah G, Adomako J, et al. (2003) An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease. Trans R Soc Trop Med Hyg 97: 159-160.
3. Connor DH, Lunn HF (1965) Mycobacterium ulcerans infection (with comments on pathogenesis). Int J Lepr 33(Suppl): 698-709.
4. Pimsler M, Sponsler TA, Meyers WM (1988) Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. J Infect Dis 157: 577-580.
5. Gunawardana G, Chatterjee D, George KM, Brennan P, Whittern D, et al. (1999) Mycolactone A and B: toxins of Mycobacterium ulcerans. J Am Chem Soc 121: 6092-6093.
6. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101: 1345-1349.
7. George KM, Chatterjee D, Gunawardana G, Welty J, Hayman R, et al. (1999) Mycolactone: A polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
8. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbio 7: 1295-1304.
9. George KM, Pascopella L, Welty DM, Small PL (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877-883.
10. Walsh DS, Meyers WM, Portaels F, Lane JE, Mongkolsirichaikul D, et al. (2005) High rates of apoptosis in human Mycobacterium ulcerans culture-positive buruli ulcer skin lesions. Am J Trop Med Hyg 73: 410-415.
11. En J, Goto M, Nakanaga K, Higashi M, Ishii N, et al. (2008) Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study. Infect Immun 76: 2002-2007.
12. Pahlevan AA, Wright DJM, Andrews C, George KM, Small PL, et al. (1999) The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T-cell cytokine production and NF-kb function. J Immunol 163: 3928-3935.
13. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7: 1187-1196.
14. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers MW, et al. (2007) Evidence of an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977-987.
15. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, et al. (2007) Mycolactone-mediated inhibition of tumour necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75: 3979-3988.
16. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, et al. (2007) Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204: 1395-1403.
17. Phillips R, Horsfield C, Kuijper S, Lartey A, Tetteh I, et al. (2005) Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol 43: 3650-3656.
18. Ribble D, Goldstein NB, Norris DA, Shellman YG (2005) A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnology 5: 5-12.
19. Hong H, Gates PJ, Staunton J, Stinear T, Cole ST, et al. (2003) Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans. Chem Commun. pp 2822-2823.
20. Hong H, Stinear T, Skelton P, Spencer JB, Leadlay PF (2005) Structure elucidation of a novel family of mycolactone toxins from the frog pathogen Mycobacterium sp. MU128FXT by mass spectrometry. Chem Commun 4306-4308.
21. Mve-Obiang A, Lee RE, Portaels F, Small PL (2003) Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 71: 774-783.
22. Sarfo FS, Phillips R, Ampadu E, Sarpong F, Adentwe E, et al. (2008) Dynamics of the cytokine response to M. ulcerans during antibiotic treatment for human M. ulcerans disease (Buruli ulcer). Clin Vaccine Immunol 16: 61-65.
23. Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadley PF, et al. (2008) Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2: e325.